Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13244
Abstract: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assess the effect of tofacitinib + conventional synthetic disease‐modifying anti rheumatic drugs (csDMARDs) on patient‐reported outcomes in Chinese patients with… read more here.
Keywords: tofacitinib conventional; conventional synthetic; disease modifying; synthetic disease ... See more keywords